Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Metadata
Title
Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States)
Authors
Polly A. Newcomb
Amy Trentham-Dietz
Publication date
01-03-2003
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 2/2003
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1023/A:1023066304473

Other articles of this Issue 2/2003

Cancer Causes & Control 2/2003 Go to the issue

OriginalPaper

Building the infrastructure for nationwide cancer surveillance and control – a comparison between The National Program of Cancer Registries (NPCR) and The Surveillance, Epidemiology, and End Results (SEER) Program (United States)

OriginalPaper

Identifying factors associated with disability-related differences in breast cancer screening (United States)

OriginalPaper

Occupation and the risk of adult glioma in the United States

OriginalPaper

Cancer in Indigenous Australians: a review

OriginalPaper

Risk of prostate cancer associated with a family history in an era of rapid increase in prostate cancer diagnosis (Australia)

OriginalPaper

Case–control study of lung cancer during 1994–1997 in the birth cohort in Tasmania, Australia, with an excess of female cases during 1983–1992
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits